thymic-factor--circulating has been researched along with Hypertension--Pulmonary* in 1 studies
1 other study(ies) available for thymic-factor--circulating and Hypertension--Pulmonary
Article | Year |
---|---|
Thymulin inhibits monocrotaline-induced pulmonary hypertension modulating interleukin-6 expression and suppressing p38 pathway.
The pathogenesis of pulmonary hypertension (PH) includes an inflammatory response. Thymulin, a zinc-dependent thymic hormone, has important immunobiological effects by inhibiting various proinflammatory cytokines and chemokines. We investigated morphological and hemodynamic effects of thymulin administration in a rat model of monocrotaline (MCT)-induced PH, as well as the pattern of proinflammatory cytokine gene expression and the intracellular pathways involved. Adult Wistar rats received an injection of MCT (60 mg/kg, sc) or an equal volume of saline. One day after, the animals randomly received during 3 wk an injection of saline, vehicle (zinc plus carboxymethyl cellulose), or thymulin (100 ng/kg, sc, daily). At d 23-25, the animals were anesthetized for hemodynamic recordings, whereas heart and lungs were collected for morphometric and molecular analysis. Thymulin prevented morphological, hemodynamic, and inflammatory cardiopulmonary profile characteristic of MCT-induced PH, whereas part of these effects were also observed in MCT-treated animals injected with the thymulin's vehicle containing zinc. The pulmonary thymulin effect was likely mediated through suppression of p38 pathway. Topics: Animals; Cytokines; Down-Regulation; Drug Evaluation, Preclinical; Heart; Hemodynamics; Hypertension, Pulmonary; Inflammation Mediators; Interleukin-6; Lung; Male; MAP Kinase Signaling System; Monocrotaline; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Thymic Factor, Circulating | 2008 |